A number of new studies have provided data on the long-term safety and efficacy of high-efficacy disease-modifying therapies in MS. The data were presented at the American Academy of Neurology (AAN) annual meeting, held April 2-7 in Seattle, Washington. The following is a summary of key studies. Read More
Neurology
AAN 2022 HIGHLIGHTS – WEDNESDAY, APRIL 6 EDITION
April 6, 2022Selected highlights from the American Academy of Neurology annual meeting, Seattle WA, 2-7 April 2022.
April 5 Edition
April 4 Edition
SPMS undertreated
NEDA not preditive of disability in RMS
Emerging concepts: spinal cord reserve
Thalamic volume affects cognitive recovery
Alemtuzumab in PMS
Clinical practice Read More
AAN 2022 HIGHLIGHTS – TUESDAY, APRIL 5 EDITION
April 5, 2022Selected highlights from the American Academy of Neurology annual meeting, Seattle WA, 2-7 April 2022.
April 6 Edition
April 4 Edition
COVID-19 boosters
MS and pregnancy
First CBT trial for MS fatigue
Clinical practice Read More
AAN 2022 HIGHLIGHTS – MONDAY, APRIL 4 EDITION
April 4, 2022Selected highlights from the American Academy of Neurology annual meeting, Seattle WA, 2-7 April 2022.
April 6 Edition
April 5 Edition
DMTs and vaccine response
Age and outcomes
Biomarkers
Radiologically isolated syndrome (RIS)
Clinical practice Read More
Ofatumumab safety update: modest effect on Ig
March 25, 2022Ofatumumab, an anti-CD20 MAb administered subcutaneously, appears to have only modest effects on serum immunoglobulins, according to an updated safety analysis from recent clinical trials (Hauser et al. Mult Scler 2022; epublished March 1, 2022). A preliminary analysis of the data was published at last year’s ECTRIMS (Wiendl et al. ECTRIMS 2021;P931) (see also ECTRIMS 2021 slide deck, NeuroSens, October 21, 2021). Read More